Nuvation Bio Inc. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
Nuvation Bio Inc. (NUVB) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of $9.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-08-06
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-06-30 was $9.00K.
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-03-31 was $8.00K, a 166.67% increase year-over-year.
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $3.00K, a 40.00% decline year-over-year.
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was $0.00.
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $5.00K.
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was -$12.00K.
- Nuvation Bio Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$139.00K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.00K 10-Q · filed 2026-08-06 | $17.00K 10-Q · filed 2026-08-06 | $20.00K derived: sum of 3 quarters · filed 2026-08-06 | $20.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-04 | $11.00K derived: sum of 2 quarters · filed 2026-05-04 | $11.00K derived: sum of 3 quarters · filed 2026-05-04 | $10.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.00K derived: sum of 2 quarters · filed 2026-03-02 | $2.00K derived: sum of 3 quarters · filed 2026-08-06 | $5.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | -$1.00K derived: sum of 2 quarters · filed 2026-08-06 | $2.00K 10-Q · filed 2025-11-03 | $7.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.00K 10-Q · filed 2026-08-06 | $2.00K 10-Q · filed 2026-08-06 | $7.00K derived: sum of 3 quarters · filed 2026-08-06 | -$4.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00K 10-Q · filed 2026-05-04 | $8.00K derived: sum of 2 quarters · filed 2026-05-04 | -$3.00K derived: sum of 3 quarters · filed 2026-05-04 | -$10.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$6.00K derived: sum of 2 quarters · filed 2026-03-02 | -$13.00K derived: sum of 3 quarters · filed 2026-03-02 | -$12.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | -$11.00K 10-Q · filed 2025-11-03 | -$18.00K derived: sum of 2 quarters · filed 2025-11-03 | -$17.00K 10-Q · filed 2025-11-03 | $27.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$7.00K 10-Q · filed 2025-08-07 | -$6.00K 10-Q · filed 2025-08-07 | $38.00K derived: sum of 3 quarters · filed 2025-08-07 | $50.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.00K 10-Q · filed 2025-05-07 | $45.00K derived: sum of 2 quarters · filed 2025-05-07 | $57.00K derived: sum of 3 quarters · filed 2025-05-07 | -$42.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $56.00K derived: sum of 2 quarters · filed 2025-03-06 | -$43.00K derived: sum of 3 quarters · filed 2025-03-06 | -$139.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $12.00K 10-Q · filed 2024-11-06 | -$87.00K derived: sum of 2 quarters · filed 2024-11-06 | -$183.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$99.00K 10-Q · filed 2024-08-05 | -$195.00K 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |